Weekly Roundup (June 4-June 8, 2012): What We Read Crossing The ‘Bridge

This Week on the DataBridge

As clinical research news filtered underneath the DataBridge, our team was hard at work assimilating the headlines and creating some of our own.

To kick off the week, we discussed how genome research could speed the pursuit of targeted therapies in oncology. Then, on Wednesday, we summarized some of the personalized medicine and clinical FSP model insights shared at EPIC 2012 in London.

 

 

Around the Web: Global News About Clinical Studies, Plus Biotech News Headlines

Without further ado, jump into our roundup of the week’s biggest clinical research news ...

One article took a look at the “winners and losers” from ASCO 2012, while another examined how drugmakers are “afflicted by Greek pain.” Drug companies have “green goals,” and “optical tweezers” could aid in discovering the mechanics of cellular communication.

Could dwindling R&D budgets boost drug discovery outsourcing?

Pharma companies begin “verified supply chain,” researchers have identified an “immune system glitch” tied to a four-fold higher likelihood of death and UK pharma is “balking at value-based pricing ideas.”

In biotech news, a piece took a look at “expanding the genetic alphabet,” while another discussed how “nanoscale protein containers” could help in drug and vaccine delivery. Computer-designed proteins can be “programmed to disarm” flu viruses, scientists look into an “export extravaganza” in human cells and researchers achieve RNA interference “in a lighter package.”

 

Targeted Therapies in Oncology Studies Highlight Week’s Stories

In oncology study news, research continues on a “novel way to treat” drug-resistant brain tumor cells, and scientists analyze the “dual effect” on tumor blood vessels. Wider testing is planned for a cancer therapy that “boosts immune system,” while intermittent hormone therapy for prostate cancer has been found to be “inferior to continuous therapy.”

Researchers have unearthed new clues about the “origin of cancer.”

Frog embryos could hold “secrets of cancer cell migration,” ginseng may “relieve cancer-related fatigue” and researchers have identified “promising biomarkers” and new therapeutic targets for kidney cancer. A new report anticipates an expected increase in cancer rates of “75% by 2030,” while another noted that the U.S. is on track to “approve more cancer drugs” in 2012.

New drugs “unleash immune system” to attack tumors, and cancer doctors say some drug shortages “have eased.” Some feel a new breast cancer drug stops tumor growth “better than standard therapy,” a test may “predict spread” of early breast cancer and an HIV drug “may slow down” metastatic breast cancer.

Doctors try to piece together “cancer’s genetic jumble” to spur personalized cancer medicine.

A report noted that there are nearly “1,000 medicines in development” to aid in the cancer fight, while “innovative fluorescence imaging” could help surgeons remove the tumor instead of the entire kidney. And finally in oncology study news, some have shared their “ASCO highlights” and top stories, and other ASCO reports note “advances in personalized cancer medicine.”

 


On the Horizon: Prepping for DIA 2012 in Philadelphia

As hard as it may be to believe, the annual DIA meeting is just a couple of weeks away. Our team is hard at work preparing the Stress Free Zone for exhibit at booth #1939 at the Philadelphia Convention Center. If you’re interested in hearing more about the clinical FSP model or our innovative approach to oncology studies, swing by our booth at DIA 2012 in Philadelphia. And feel free to drop us a line if you’re interested in setting up a demo of our nowEDC™ system during your time at DIA from June 24-28.

 

So what did we miss this week? Did you see anything intriguing at EPIC 2012 that you’d like to share? Were there any articles or blog posts related to news about clinical studies this week that slipped past us?

Please feel free to share your thoughts and links in the comments section below, and hit us up on Twitter to get the latest industry news. As always, thanks for visiting the DataBridge ... and have a great weekend!